Literature DB >> 16083257

Proteomics: from basic research to diagnostic application. A review of requirements & needs.

Frank Vitzthum1, Fritz Behrens, N Leigh Anderson, John H Shaw.   

Abstract

For several years proteomics research has been expected to lead to the finding of new markers that will translate into clinical tests applicable to samples such as serum, plasma and urine: so-called in vitro diagnostics (IVDs). Attempts to implement technologies applied in proteomics, in particular protein arrays and surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS), as IVD instruments have initiated constructive discussions on opportunities and challenges inherent in such a translation process also with respect to the use of multi-marker profiling approaches and pattern signatures in IVD. Taking into account the role that IVD plays in health care, we describe IVD requirements and needs. Subject to stringent costs versus benefit analyses, IVD has to provide reliable information about a person's condition, prognosis or risk to suffer a disease, thus supporting decisions on treatment or prevention. It is mandatory to fulfill requirements in routine IVD, including disease prevention, diagnosis, prognosis, and treatment monitoring or follow up among others. To fulfill IVD requirements, it is essential to (1) provide diagnostic tests that allow for definite and reliable diagnosis tied to a decision on interventions (prevention, treatment, or nontreatment), (2) meet stringent performance characteristics for each analyte (in particular test accuracy, including both precision of the measurement and trueness of the measurement), and (3) provide adequate diagnostic accuracy, i.e., diagnostic sensitivity and diagnostic specificity, determined by the desired positive and negative predictive values which depend on disease frequency. The fulfillment of essential IVD requirements is mandatory in the regulated environment of modern diagnostics. Addressing IVD needs at an early stage can support a timely and effective transition of findings and developments into routine diagnosis. IVD needs reflect features that are useful in clinical practice. This helps to generate acceptance and assists the implementation process. On the basis of IVD requirements and needs, we outline potential implications for clinical proteomics focused on applied research activities.

Entities:  

Mesh:

Year:  2005        PMID: 16083257     DOI: 10.1021/pr050080b

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  25 in total

Review 1.  The future of biological mass spectrometry.

Authors:  Marvin L Vestal
Journal:  J Am Soc Mass Spectrom       Date:  2011-04-09       Impact factor: 3.109

2.  Selectivity of labeled bromoethylamine for protein alkylation.

Authors:  Simona Marincean; Montserrat Rabago Smith; Laci Beltz; Babak Borhan
Journal:  J Mol Model       Date:  2012-05-29       Impact factor: 1.810

Review 3.  A proteomic primer for the clinician.

Authors:  Yurong Guo; Zongming Fu; Jennifer E Van Eyk
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 4.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

5.  Efficient sample preparation in immuno-matrix-assisted laser desorption/ionization mass spectrometry using acoustic trapping.

Authors:  Björn Hammarström; Hong Yan; Johan Nilsson; Simon Ekström
Journal:  Biomicrofluidics       Date:  2013-03-28       Impact factor: 2.800

6.  Performance comparisons of nano-LC systems, electrospray sources and LC-MS-MS platforms.

Authors:  Qian Liu; Jennifer S Cobb; Joshua L Johnson; Qi Wang; Jeffrey N Agar
Journal:  J Chromatogr Sci       Date:  2013-01-17       Impact factor: 1.618

7.  Diagnostic model of saliva protein finger print analysis of patients with gastric cancer.

Authors:  Zheng-Zhi Wu; Ji-Guo Wang; Xiao-Li Zhang
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 8.  Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Authors:  Yahui Liu; Hong Qing; Yulin Deng
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923

9.  Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders.

Authors:  Abhilash Venugopal; Raghothama Chaerkady; Akhilesh Pandey
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

Review 10.  The proteogenomic path towards biomarker discovery.

Authors:  Tara K Sigdel; Minnie M Sarwal
Journal:  Pediatr Transplant       Date:  2008-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.